John Oyler Sells 4,940 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 4,940 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40. Following the sale, the chief executive officer owned 1,120 shares of the company’s stock, valued at $303,027.20. This trade represents a 81.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $260.27 on Friday. The firm has a market cap of $28.56 billion, a P/E ratio of 58.23 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average price is $300.30 and its 200 day moving average price is $314.98. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. On average, equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Trading of BeOne Medicines

Large investors have recently bought and sold shares of the company. EFG International AG purchased a new stake in shares of BeOne Medicines in the 4th quarter worth about $25,000. Leonteq Securities AG purchased a new position in BeOne Medicines during the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth about $35,000. CWM LLC raised its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines in the fourth quarter valued at about $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ONC. Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Barclays upped their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wolfe Research started coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective for the company. Finally, Guggenheim boosted their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.